In the evaluation of a testicular mass, which test best helps distinguish malignant from benign scrotal conditions?

• A. Serum Alpha Fetoprotein
• B. Serum Human Chorionic Gonadotropin
• C. Ultrasound of the Scrotum
• D. CT Scan of the Pelvis

Answer: (C)

The main concept is that imaging with high-resolution scrotal ultrasound is the most informative single test for evaluating a scrotal mass. It provides detailed anatomic information to determine whether the lesion arises within the testicle or from surrounding structures, and it can characterize the mass as cystic or solid. This distinction is crucial because intratesticular solid masses are much more concerning for malignancy, while many extratesticular or cystic lesions are benign. Doppler adds another layer by showing vascularity; tumors often have blood flow that helps separate them from avascular or inflamed tissues, though vascular patterns aren’t perfect, they are highly helpful in context.

Blood tests for tumor markers (such as AFP and hCG) complement imaging by informing potential tumor types and guiding management, but they don’t reliably separate benign from malignant on their own—some cancers may not elevate markers, and some benign conditions don’t cause marker changes. CT scans are useful for staging if cancer is known or suspected but aren’t the best initial test to distinguish benign from malignant scrotal conditions. So, ultrasound stands out as the best first-step tool to differentiate malignant from benign scrotal pathology due to its ability to precisely localize, characterize, and assess blood flow of the lesion.